OakChart

Maze Therapeutics Inc

MAZEHealthcare·Biotechnology·USA·Mid·NASD·Nov 11 • 3:59 PM ET

36.73+1.28 (3.61%)
2026-11-12 02:07 CET
Market cap
2,040.32 USD m
Revenue, TTM
20.00 USD m
Net income, TTM
-151.47 USD m
Free cash flow, TTM
-115.26 USD m
EPS diluted, TTM
-2.70
P/E
-
Compare

Price

MAZE against its 20, 50 and 200-day averages
2050200beatmiss
25.0030.0035.001.8M3.6MVolumeMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26MAZEclose 36.7320-day 32.0250-day 28.33200-day 31.4636.7352w low

31.5% under the 52-week high of 53.65 on 16 Mar 2026. 52-week low 21.95 on 21 Sep 2026. Last 15 sessions, 25.7% high to low

Volume 0.71× normal · the line is the 50-bar volume average

Profile

MAZE
52-week range, 47% of the way up
21.9553.65

Maze Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular, and related metabolic, or CVRM diseases. Its pipeline includes the Compass platform, which allows it to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process to refer a variant functionalization. The company was founded by Mark Daly, Aaron D. Gitler, Stephen Elledge, Sekar Kathiresan, and Jonathan S. Weissman on August 29, 2017 and is headquartered in San Francisco, CA.

IndexRUT
Employees141
IPOJan 31, 2025
Beta1.96
ATR, 14d1.74
Rel volume0.71
Short float19.69%
Insider own37.91%
Inst own70.73%

Snapshot

6 groups

Valuation

IndexRUT
Market Cap2.01B
Enterprise Value1.68B
Income-151.47M
Sales20.00M
Book/sh7.59
Cash/sh7.13
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees141
IPOJan 31, 2025

Ratios

P/E-
Forward P/E-
PEG-
P/S100.43
P/B4.84
P/C5.15
P/FCF-
EV/EBITDA-
EV/Sales83.92
Quick Ratio14.14
Current Ratio14.14
Debt/Eq0.14
LT Debt/Eq0.13
Option/ShortYes / Yes

Earnings

EPS (ttm)-2.70
EPS next Y-3.35
EPS next Q-0.83
EPS this Y7.83%
EPS next Y-19.00%
EPS next 5Y-6.41%
EPS past 3/5Y-0.41% -
Sales past 3/5Y- -
EPS Y/Y TTM-19.59%
Sales Y/Y TTM700.00%
EPS Q/Q-25.93%
Sales Q/Q-
EarningsNov 09 AMC
EPS/Sales Surpr.-4.03% -

Ownership

Insider Own37.91%
Insider Trans-2.01%
Inst Own70.73%
Inst Trans10.57%
ROA-32.45%
ROE-37.49%
ROIC-31.34%
Gross Margin91.40%
Oper. Margin-820.82%
Profit Margin-757.36%
SMA2014.71%
SMA5029.67%
SMA20016.77%
Trades-

Technical

Shs Outstand56.45M
Shs Float33.95M
Short Float19.69%
Short Ratio9.81
Short Interest6.68M
52W High53.65 -31.54%
52W Low21.95 67.33%
Volatility6.11% 5.52%
ATR (14)1.74
RSI (14)73.85
Beta1.96
Rel Volume0.71
Avg Volume681.69K
Volume484,188

Performance

Perf Week10.04%
Perf Month37.77%
Perf Quarter32.77%
Perf Half Y36.24%
Perf YTD-11.34%
Perf Year13.86%
Perf 3Y-
Perf 5Y-
Perf 10Y-
Recom1.00
Target Price62.46
Prev Close35.45
Price36.73
Change %3.61%

Analyst ratings

latest 9 of 9
DateActionAnalystRating changeTargetImplied
Oct 19, 2026InitiatedCCanaccord GenuityBuy$75+104.2%
Sep 23, 2026InitiatedCCitigroupBuy$50+36.1%
Mar 18, 2026InitiatedTTruistBuy$68+85.1%
Mar 10, 2026InitiatedMMizuhoOutperform$97+164.1%
Dec 04, 2025InitiatedWWells FargoOverweight$55+49.7%
Nov 14, 2025InitiatedRRaymond JamesOutperform
Sep 02, 2025InitiatedBBTIG ResearchBuy$30-18.3%
Jul 23, 2025InitiatedHH.C. WainwrightBuy$34-7.4%
Jul 08, 2025InitiatedWWedbushOutperform$17-53.7%

Peers

Mkt cap
TickerCompanyMkt cap
TVTXTravere Therapeutics Inc5.00B
VERAVera Therapeutics Inc2.20B
VRTXVertex Pharmaceuticals Inc138.69B
PROKProKidney Corp341.68M
JBIOJade Biosciences Inc1.05B
MLYSMineralys Therapeutics Inc1.43B
ARDXArdelyx Inc786.79M
DNLIDenali Therapeutics Inc3.16B
CLYMClimb Bio Inc719.55M
ADRXADARx Pharmaceuticals Inc1.47B

Insider trading

latest 14 of 100
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
Coloma Jason VChief Executive OfficerNov 02 '26Sale30.2534,5011,043,76612,965Nov 04 04:13 PM
Coloma Jason VOfficerNov 02 '26Proposed Sale31.7034,5011,093,682Nov 02 04:04 PM
Dandekar AtulCSBOOct 29 '26Option Exercise10.427,50078,15039,816Oct 30 04:14 PM
Dandekar AtulCSBOOct 29 '26Sale32.077,500240,53232,316Oct 30 04:14 PM
ATUL DANDEKAROfficerOct 29 '26Proposed Sale31.7315,000475,950Oct 29 04:21 PM
Coloma Jason VChief Executive OfficerOct 01 '26Sale27.0234,501932,26015,558Oct 02 04:12 PM
Bernstein HaroldPresident, R&D & CMOOct 01 '26Option Exercise10.4216,141168,18916,141Oct 02 04:09 PM
Bernstein HaroldPresident, R&D & CMOOct 01 '26Sale26.9316,141434,7430Oct 02 04:09 PM
HAROLD BERNSTEINOfficerOct 01 '26Proposed Sale27.1816,141438,712Oct 01 04:21 PM
Dandekar AtulCSBOSep 29 '26Option Exercise10.427,50078,15039,816Oct 01 04:06 PM
Dandekar AtulCSBOSep 29 '26Sale27.067,500202,92132,316Oct 01 04:06 PM
Coloma Jason VOfficerOct 01 '26Proposed Sale27.0534,501933,252Oct 01 04:02 PM
Bernstein HaroldPresident, R&D & CMOSep 04 '26Sale26.229,705254,5020Sep 08 04:20 PM
HAROLD BERNSTEINOfficerSep 04 '26Proposed Sale25.879,705251,068Sep 04 04:34 PM

Held by

AUM
TickerCompanyAUM
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
IWMiShares Russell 2000 Index FundAUM: 77.38B
XPHState Street SPDR S&P Pharmaceuticals ETFAUM: 516.35M
VXFVanguard Extended Market Index ETFAUM: 30.47B
IWOiShares Russell 2000 Growth ETFAUM: 14.06B
IBBiShares Biotechnology ETFAUM: 11.36B
SCHASchwab U.S. Small-Cap ETFAUM: 22.25B
VTWOVanguard Russell 2000 Index ETFAUM: 16.75B
IHEiShares U.S. Pharmaceuticals ETFAUM: 1.72B
FYCFirst Trust Small Cap Growth AlphaDEX FundAUM: 1.35B

News

latest 14 of 104

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-11-09-0.790-0.759-0.7900.000.0013
2026Q22026-08-11-0.760-0.717-0.7580.002.8611
2026Q12026-05-12-0.450-0.577-0.44920.0010.6311
2025Q42026-03-25-0.650-0.714-0.7010.000.0012
2025Q32025-11-06-0.660-0.708-0.6260.000.007
2025Q22025-08-12-0.770-0.836-0.7680.003.136
2025Q12025-05-14-1.150-0.723-0.7490.000.004
2024Q42025-03-31-18.3202.050-0.1120.000.002
2026Q4---0.831--0.0013
2027Q1---0.804--2.549
2027Q2---0.820--2.549
2027Q3---0.854--2.549
2027Q4---0.838--4.589

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2024FY1.250-7.8830.078167.5167.67
2025FY-3.050-3.119-3.1100.000.00
2026FY--2.811--20.00
2027FY--3.345--9.73
2028FY--3.675--10.11
2029FY--3.769--43.70
2030FY--2.778--196.07

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q4S2026-11-109000.000.000.00
2026Q4S2026-11-099000.000.000.00
2026Q4S2026-10-169000.000.000.00
2026Q4S2026-09-238000.000.000.00
2026Q4S2026-08-127000.000.000.00
2026Q4S2026-07-277000.000.000.00
2026Q4S2026-07-057010.000.000.00
2026Q4S2026-06-138010.000.000.00
2026Q4S2026-05-139010.330.003.00
2026Q4S2026-04-068101.000.005.00
2026Q4S2026-03-278100.380.003.00
2026Q4S2026-03-257100.430.003.00
2026Q4S2026-03-167000.430.003.00
2026Q4S2026-02-236000.500.003.00

Estimate history

EPS, annual-2.626-2.2940.078-2.658-2.6961
Period2022202320242025TTM
EPS, quarterly-0.055-0.112-0.749-0.768-0.626-0.701-0.449-0.758-0.788
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Sales, annual00167.5020
Period2022202320242025TTM
Sales, quarterly2.5000002000
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Shares, annual43.77743.77743.79649.33656.449
Period2022202320242025MRQ
Shares, quarterly43.77743.79643.79743.85148.07749.33649.73855.50556.449
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY
Total Revenue20.000.00167.500.000.00
Cost of Goods Sold Incl. D&A1.722.403.304.093.82
Gross Profit18.28-2.40164.20-4.09-3.82
Selling, General and Administrative Excl. Other182.44140.50106.6294.46107.21
Research and Development135.66108.4583.5073.9488.19
Other Operating Expense0.000.000.000.000.00
Operating Income-164.16-142.9057.59-98.55-111.03
Interest Expense2.770.00---
Unusual Expense0.000.008.443.832.40
Net Income Before Taxes-151.47-131.1253.40-100.42-114.94
Income Taxes0.000.001.170.000.00
Consolidated Net Income-151.47-131.1218.38-100.42-114.94
Net Income From Continuing Operations-151.47-131.1218.38-100.42-114.94
Net Income-151.47-131.123.40-100.42-114.94
EPS (Recurring)-2.49-2.660.21-2.23-2.59
EPS (Basic, Before Extraordinaries)-2.70-2.660.08-2.29-2.63
EPS (Diluted)-2.70-2.660.08-2.29-2.63
EBITDA-162.44-140.5060.88-94.46-107.21
Non-Operating Income (Expense)15.4611.784.251.97-1.51
Other After Tax Adjustments0.000.00-33.850.000.00
Stock Option Compensation Expense30.9116.407.628.756.74
Price To Sales Ratio82.72----
Gross Margin91.40-98.03--
Operating Margin-820.82-34.38--
Net Margin-757.36-2.03--
Shares Outstanding56.4549.3443.8043.7843.78
Market Capitalization2,040.322,040.321,927.18--

Income statement, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q22025Q12024Q4
Total Revenue0.000.0020.000.000.000.000.000.00
Cost of Goods Sold Incl. D&A0.390.390.440.500.570.650.680.70
Gross Profit-0.39-0.3919.56-0.50-0.57-0.65-0.68-0.70
Selling, General and Administrative Excl. Other51.1347.6446.1137.5632.3935.8334.7229.02
Research and Development39.8434.5533.7027.5725.1928.1127.5822.22
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-51.52-48.03-26.55-38.06-32.97-36.47-35.40-29.73
Interest Expense0.970.930.870.00----
Unusual Expense0.000.000.000.00-0.20-0.100.001.54
Net Income Before Taxes-47.97-44.73-24.21-34.57-30.09-33.68-32.79-29.85
Income Taxes0.000.000.000.000.000.000.00-0.28
Consolidated Net Income-47.97-44.73-24.21-34.57-30.09-33.68-32.7910.07
Net Income From Continuing Operations-47.97-44.73-24.21-34.57-30.09-33.68-32.7910.07
Net Income-47.97-44.73-24.21-34.57-30.09-33.68-32.79-4.91
EPS (Recurring)-0.79-0.76-0.45-0.70-0.63-0.77-0.75-0.09
EPS (Basic, Before Extraordinaries)-0.79-0.76-0.45-0.70-0.63-0.77-0.75-0.11
EPS (Diluted)-0.79-0.76-0.45-0.70-0.63-0.77-0.75-0.11
EBITDA-51.13-47.64-26.11-37.56-32.39-35.83-34.72-29.02
Non-Operating Income (Expense)4.524.243.213.492.682.692.621.42
Other After Tax Adjustments0.000.000.000.000.000.000.0039.65
Stock Option Compensation Expense8.549.197.116.073.863.243.232.25
Price To Sales Ratio82.7288.0280.44--215.22--
Gross Margin--97.78-----
Operating Margin---132.76-----
Net Margin---121.04-----
Shares Outstanding56.4555.5049.7449.3448.0843.8543.8043.80
Market Capitalization2,040.321,651.501,483.801,993.591,137.05537.39481.98499.93

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY
Cash & Short Term Investments341.92196.8129.1699.92
Short Term Receivables1.500.000.000.00
Inventories0.000.000.000.00
Other Current Assets6.304.864.956.23
Total Current Assets349.72201.6734.11106.15
Net Property, Plant & Equipment25.1629.9234.9841.23
Total Investments and Advances19.201.091.091.21
Other Assets3.057.871.321.37
Total Assets397.13240.5471.50149.96
Short Term Debt Incl. Current Port. of LT Debt4.794.634.494.32
Accounts Payable1.791.942.021.58
Other Current Liabilities15.9714.109.8114.87
Total Current Liabilities22.5620.6716.3220.78
Long Term Debt18.5122.0045.1327.73
Provision for Risks Charges0.000.000.000.00
Other Liabilities1.090.970.000.00
Total Liabilities42.1643.6461.4548.51
Non-Equity Reserves0.000.000.000.00
Preferred Stock - Carrying Value0.00508.09383.90383.90
Common Equity354.97-311.18-373.85-282.46
Total Shareholders Equity354.97196.9010.05101.44
Accumulated Minority Interest0.000.000.000.00
Total Equity354.97196.9010.05101.44
Total Liabilities & Stockholders Equity397.13240.5471.50149.96
Book Value Per Share7.19-7.11-8.54-6.45
Tangible Book Value Per Share7.19-7.11-8.54-6.45
Full-Time Employees141125--
Price to Book Ratio4.845.07--
Return on Assets-41.1211.78-90.68-
Return on Equity-47.5217.76-180.12-
Return on Invested Capital-35.118.40-181.95-88.98
Quick Ratio15.509.762.095.11
Current Ratio15.509.762.095.11

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY
Net Income-151.47-131.1252.23-100.42-114.94
Depreciation1.722.403.304.093.82
Other Funds (Non Cash)34.5619.0521.9515.8115.15
Funds from Operations-115.20-109.6777.48-80.51-95.97
Extraordinary Item0.000.000.000.000.00
Changes in Working Capital0.46-2.27-1.52-6.32-3.24
Cash from Operating Activities-114.74-111.9475.95-86.83-99.20
Capital Expenditures-0.52-0.79-1.15-0.44-1.97
Net Assets From Acquisitions0.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.00
Purchase or Sale of Investments-256.51-170.170.000.00-1.20
Purchase of Investments-375.01-187.670.000.00-1.20
Sale Or Maturity of Investments118.5017.500.000.000.00
Other Uses0.000.000.000.000.00
Other Sources0.000.000.000.000.00
Cash from Investing Activities-257.03-170.96-1.15-0.44-3.17
Cash Dividends Paid0.000.000.000.000.00
Change in Capital Stock170.69275.8468.370.211.73
Repurchase of Common Pref Stock0.000.000.000.000.00
Sale of Common Pref Stock170.69275.8468.370.211.73
Proceedsfrom Stock Options160.32270.2767.640.001.57
Issuance or Reduction of Debt, Net38.460.0024.4816.180.00
Change in Long Term Debt38.460.0024.4816.180.00
Issuance of Long Term Debt38.460.0024.4816.180.00
Reduction of Long Term Debt0.000.000.000.000.00
Net Financing Active Other Cash Flow0.00-0.500.000.000.00
Other Financing Activities Uses0.00-0.500.000.000.00
Cash from Financing Activities209.15275.3492.8516.391.73
Net Change in Cash-162.62-7.57167.65-70.88-100.64
Free Cash Flow-115.26-112.7374.81-87.27-101.17
Preferred Dividends (Cash Flow)-0.00-0.000.00
Deferred Taxes & Investment Tax Credit-0.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Cash & Short Term Investments389.66411.09352.38341.92383.94264.54
Short Term Receivables3.202.8021.801.500.700.00
Inventories0.000.000.000.000.000.00
Other Current Assets7.246.545.606.306.676.61
Total Current Assets400.10420.42379.78349.72391.30271.15
Net Property, Plant & Equipment21.9422.8323.9725.1626.4627.71
Total Investments and Advances88.4184.9111.6419.201.091.09
Other Assets1.103.464.323.053.213.57
Total Assets511.56531.62419.71397.13422.06303.52
Short Term Debt Incl. Current Port. of LT Debt4.934.884.844.794.764.72
Accounts Payable4.572.214.011.792.923.67
Other Current Liabilities18.8015.8712.3815.9714.4311.52
Total Current Liabilities28.3022.9621.2422.5622.1119.90
Long Term Debt54.7155.5456.3818.5119.4220.29
Provision for Risks Charges0.000.000.000.000.000.00
Other Liabilities0.000.000.391.091.091.09
Total Liabilities83.0178.5078.0142.1642.6241.28
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity428.55453.12341.70354.97379.44262.24
Total Shareholders Equity428.55453.12341.70354.97379.44262.24
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity428.55453.12341.70354.97379.44262.24
Total Liabilities & Stockholders Equity511.56531.62419.71397.13422.06303.52
Book Value Per Share7.598.166.877.197.895.98
Tangible Book Value Per Share7.598.166.877.197.895.98
Full-Time Employees---141--
Price to Book Ratio4.844.344.155.254.341.84
Return on Assets-32.45-31.99-32.57-41.12-28.15-
Return on Equity-37.49-37.35-38.67-47.52-36.13-
Return on Invested Capital-9.93-8.79-6.08-9.26-7.54-11.92
Quick Ratio14.1418.3117.8815.5017.7013.63
Current Ratio14.1418.3117.8815.5017.7013.63

Cash flow, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Net Income-47.97-44.73-24.21-34.57-30.09-33.68
Depreciation0.390.390.440.500.570.65
Other Funds (Non Cash)9.4210.168.336.654.374.02
Funds from Operations-38.17-34.17-15.44-27.42-25.14-29.01
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital5.3319.12-23.68-0.310.50-1.04
Cash from Operating Activities-32.84-15.05-39.11-27.73-24.64-30.05
Capital Expenditures-0.29-0.11-0.09-0.03-0.07-0.39
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments-31.12-128.406.37-103.35-66.810.00
Purchase of Investments-68.12-162.40-23.63-120.85-66.810.00
Sale Or Maturity of Investments37.0034.0030.0017.500.000.00
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities-31.41-128.516.28-103.39-66.88-0.39
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock15.77147.493.843.59143.760.61
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock15.77147.493.843.59143.760.61
Proceedsfrom Stock Options14.60145.79-0.240.16141.750.61
Issuance or Reduction of Debt, Net0.00-0.0538.520.000.000.00
Change in Long Term Debt0.00-0.0538.520.000.000.00
Issuance of Long Term Debt0.00-0.0538.520.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.00
Cash from Financing Activities15.77147.4442.363.59143.760.61
Net Change in Cash-48.493.889.52-127.5352.23-29.83
Free Cash Flow-33.13-15.16-39.21-27.76-24.71-30.45

Revenue breakdown

Biological Products, (No Diagnostic Substances)2024: 167.50M
United States2024: 167.50M

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-3019.38%6.7M34.5M657.73K
2026-10-1521.83%7.5M34.5M587.87K
2026-09-3019.04%6.6M34.5M570.63K
2026-09-1516.48%5.7M34.5M551.48K
2026-08-3117.24%5.9M34.3M548.01K
2026-08-1417.41%6.0M34.4M561.59K
2026-07-3116.44%5.7M34.5M590.10K
2026-07-1516.01%5.5M34.5M668.10K
2026-06-3016.02%5.5M34.5M742.70K
2026-06-1511.78%4.1M34.5M851.74K
2026-05-2911.33%3.9M34.4M862.86K
2026-05-1511.50%4.0M34.4M852.50K
2026-04-3013.90%4.3M31.3M869.39K
2026-04-1513.48%3.8M28.2M820.14K
2026-03-3114.18%3.9M27.4M704.70K
2026-03-1313.52%3.6M26.6M481.40K
2026-02-2712.95%3.4M26.6M450.44K
2026-02-1312.64%3.4M26.6M464.77K
2026-01-3010.50%2.7M26.1M427.71K
2026-01-159.88%2.6M26.1M395.98K

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call12.5022.5026.500.007.6330.000.000.966-0.1190.004
call15.0020.0024.000.006.4950.000.000.959-0.1170.005
call17.5017.5021.500.005.5680.000.000.951-0.1150.006
call20.0015.0019.000.004.7820.000.000.942-0.1110.007
call22.5012.5016.507.804.09523.000.000.931-0.1070.008
call25.0010.0014.504.413.8283000.000.917-0.1020.009
call30.005.709.307.002.55876432.000.872-0.0880.012
call35.001.905.002.850.89879.002.000.623-0.2330.022
call40.000.004.701.251.8697.000.000.437-0.2320.023
call45.000.004.900.452.5765.000.000.367-0.3050.021
call50.000.004.900.503.0555.000.000.332-0.3480.021
call55.000.004.900.103.15065.000.000.282-0.3450.019
call60.000.004.900.252.15672.000.000.098-0.1210.010
call65.000.004.900.502.43238.000.000.090-0.1240.009
call70.000.004.900.502.6494.000.000.085-0.1290.009
call75.000.004.900.202.8466.000.000.080-0.1330.008
put12.500.004.900.2010.8612.000.00-0.070-0.4550.008
put15.000.004.900.309.1834.000.00-0.092-0.4720.009
put17.500.004.901.657.9701.000.00-0.114-0.4800.011
put20.000.004.900.006.8880.000.00-0.139-0.4750.013
put22.500.004.900.055.9657.000.00-0.165-0.4630.014
put25.000.004.900.105.1543150.00-0.195-0.4440.016
put30.000.105.001.601.2586440.00-0.128-0.0840.012
put35.000.104.908.502.2283.000.00-0.377-0.2290.022
put40.003.204.1013.700.88421.000.00-0.563-0.2280.023
put45.006.6010.000.001.9100.000.00-0.628-0.3020.022
put50.0011.3015.0021.882.3750.000.00-0.666-0.3480.021
put55.0016.3020.000.002.7610.000.00-0.718-0.3390.019
put60.0021.7025.000.003.0950.000.00-0.902-0.1140.010
put65.0026.6030.000.003.3890.000.00-0.909-0.1200.009
put70.0031.2035.0046.003.6500.000.00-0.915-0.1240.009
put75.0036.6040.000.003.8880.000.00-0.920-0.1280.009

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-0910-QQuarterly report pursuant to Section 13 or 15(d)2026-09-30SEC
2026-11-098-KCurrent report2026-11-09SEC
2026-11-044Statement of changes in beneficial ownership of securities2026-11-02SEC
2026-11-02144Filing for proposed sale of securities under Rule 144.SEC
2026-10-304Statement of changes in beneficial ownership of securities2026-10-29SEC
2026-10-29144Filing for proposed sale of securities under Rule 144.SEC
2026-10-168-KCurrent report2026-10-15SEC
2026-10-024Statement of changes in beneficial ownership of securities2026-10-01SEC
2026-10-024Statement of changes in beneficial ownership of securities2026-10-01SEC
2026-10-014Statement of changes in beneficial ownership of securities2026-09-29SEC
2026-10-01144Filing for proposed sale of securities under Rule 144.SEC
2026-10-01144Filing for proposed sale of securities under Rule 144.SEC
2026-09-084Statement of changes in beneficial ownership of securities2026-09-04SEC
2026-09-044Statement of changes in beneficial ownership of securities2026-09-02SEC
2026-09-044Statement of changes in beneficial ownership of securities2026-09-02SEC
2026-09-04144Filing for proposed sale of securities under Rule 144.SEC
2026-09-044Statement of changes in beneficial ownership of securities2026-09-02SEC
2026-09-044Statement of changes in beneficial ownership of securities2026-09-02SEC
2026-09-034Statement of changes in beneficial ownership of securities2026-09-01SEC
2026-09-034Statement of changes in beneficial ownership of securities2026-09-01SEC
2026-09-034Statement of changes in beneficial ownership of securities2026-09-01SEC
2026-09-034Statement of changes in beneficial ownership of securities2026-09-01SEC
2026-09-02144Filing for proposed sale of securities under Rule 144.SEC
2026-09-02144Filing for proposed sale of securities under Rule 144.SEC
2026-09-02144Filing for proposed sale of securities under Rule 144.SEC
2026-09-02144Filing for proposed sale of securities under Rule 144.SEC
2026-09-01144Filing for proposed sale of securities under Rule 144.SEC
2026-08-314Statement of changes in beneficial ownership of securities2026-08-28SEC
2026-08-174Statement of changes in beneficial ownership of securities2026-08-13SEC
2026-08-173Initial statement of beneficial ownership of securities2026-08-13SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-11001.04M1
2026-10001.61M3
2026-09002.93M12
2026-08001.57M3
2026-07001.68M3
2026-06001.49M5
2026-05001.49M5
2026-0400705.81K3
2026-03002.47M3
2026-0200920.55K2
2026-01003.11M8
2025-12005.37M5
2025-110000

Institutional holders

Manager% owned
Frazier Life Sciences Management, L.P.9.09%
TRV GP IV, LLC8.08%
ARCH Venture Management, LLC7.44%
Deep Track Capital, LP6.74%
BlackRock, Inc.6.33%
Jupiter Topco LLC6.16%
T. Rowe Price Investment Management, Inc.4.70%
Logos Global Management LP3.50%
VANGUARD CAPITAL MANAGEMENT LLC3.21%
a16z Capital Management, L.L.C.3.08%

Funds

Fund% owned
VANGUARD TOTAL STOCK MARKET INDEX FUND2.55%
T. Rowe Price Capital Appreciation Fund1.77%
iShares Russell 2000 ETF1.66%
Select Biotechnology Portfolio1.42%
JPMorgan Small Cap Growth Fund0.76%
Fidelity Small Cap Index Fund0.70%
VANGUARD EXTENDED MARKET INDEX FUND0.59%
T. Rowe Price Small-Cap Stock Fund, Inc.0.53%
iShares Russell 2000 Growth ETF0.50%
T. Rowe Price Small-Cap Value Fund, Inc.0.50%

OakChart. MAZE. Cached 15 minutes.